NanoSphere Health Sciences Inc. (NSHSF)
USD 0.04
(-60.0%)
USD 0.04
(-60.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -220.07 Thousand USD | 23.05% |
| 2022 | -286 Thousand USD | 26.31% |
| 2021 | -388.08 Thousand USD | 28.12% |
| 2020 | -539.87 Thousand USD | 83.32% |
| 2019 | -3.23 Million USD | 28.29% |
| 2018 | -4.51 Million USD | -293.72% |
| 2017 | -1.14 Million USD | -82.21% |
| 2016 | -629.05 Thousand USD | -540.03% |
| 2015 | -98.28 Thousand USD | 28.28% |
| 2014 | -137.03 Thousand USD | -103.21% |
| 2013 | 4.27 Million USD | 414.18% |
| 2012 | -1.36 Million USD | -146.9% |
| 2011 | 2.9 Million USD | 1574.47% |
| 2010 | -196.71 Thousand USD | -32.6% |
| 2009 | -148.34 Thousand USD | 97.44% |
| 2008 | -5.79 Million USD | -398.14% |
| 2007 | -1.16 Million USD | -3632.9% |
| 2006 | -31.15 Thousand USD | -22.82% |
| 2005 | -25.36 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -31.86 Thousand USD | 51.06% |
| 2024 Q2 | -56.7 Thousand USD | -63.38% |
| 2023 FY | -241.13 Thousand USD | 15.69% |
| 2023 Q3 | -63.86 Thousand USD | -14.26% |
| 2023 Q4 | -65.11 Thousand USD | -1.95% |
| 2023 Q1 | -53.91 Thousand USD | 61.36% |
| 2023 Q2 | -55.89 Thousand USD | -3.68% |
| 2022 Q3 | -1463.00 USD | 97.87% |
| 2022 FY | -286 Thousand USD | 26.31% |
| 2022 Q2 | -68.75 Thousand USD | 9.82% |
| 2022 Q1 | -76.24 Thousand USD | 77.35% |
| 2022 Q4 | -139.53 Thousand USD | -9437.87% |
| 2021 Q1 | -72.94 Thousand USD | 44.23% |
| 2021 Q2 | -164.5 Thousand USD | -125.53% |
| 2021 Q3 | 186.01 Thousand USD | 213.08% |
| 2021 FY | -388.08 Thousand USD | 28.12% |
| 2021 Q4 | -336.66 Thousand USD | -280.98% |
| 2020 FY | -539.87 Thousand USD | 83.32% |
| 2020 Q1 | -217.93 Thousand USD | 80.42% |
| 2020 Q2 | -119.7 Thousand USD | 45.07% |
| 2020 Q3 | -71.44 Thousand USD | 40.32% |
| 2020 Q4 | -130.78 Thousand USD | -83.06% |
| 2019 Q2 | -520.89 Thousand USD | 29.58% |
| 2019 Q4 | -1.11 Million USD | -29.06% |
| 2019 FY | -3.23 Million USD | 28.29% |
| 2019 Q1 | -739.72 Thousand USD | 62.75% |
| 2019 Q3 | -862.34 Thousand USD | -65.55% |
| 2018 FY | -4.51 Million USD | -293.72% |
| 2018 Q1 | -995.66 Thousand USD | -35.38% |
| 2018 Q4 | -1.98 Million USD | -176.87% |
| 2018 Q3 | -717.23 Thousand USD | 11.89% |
| 2018 Q2 | -814.06 Thousand USD | 18.24% |
| 2017 FY | -1.14 Million USD | -82.21% |
| 2017 Q4 | -735.47 Thousand USD | -730.82% |
| 2017 Q2 | -227.15 Thousand USD | -190.58% |
| 2017 Q1 | -78.17 Thousand USD | 5.07% |
| 2017 Q3 | -88.52 Thousand USD | 61.03% |
| 2016 Q3 | -465.52 Thousand USD | -838.42% |
| 2016 FY | -629.05 Thousand USD | -540.03% |
| 2016 Q1 | -32.78 Thousand USD | -143.45% |
| 2016 Q4 | -82.34 Thousand USD | 82.31% |
| 2016 Q2 | -49.6 Thousand USD | -51.29% |
| 2015 Q4 | -13.46 Thousand USD | 29.64% |
| 2015 Q3 | -19.14 Thousand USD | 53.98% |
| 2015 Q1 | -28.81 Thousand USD | -114.22% |
| 2015 Q2 | -41.59 Thousand USD | -44.35% |
| 2015 FY | -98.28 Thousand USD | 28.28% |
| 2014 FY | -137.03 Thousand USD | -103.21% |
| 2014 Q2 | -69.45 Thousand USD | -83.92% |
| 2014 Q1 | -37.76 Thousand USD | -105.7% |
| 2014 Q4 | 202.57 Thousand USD | 185.9% |
| 2014 Q3 | -235.82 Thousand USD | -239.56% |
| 2013 Q4 | 662.02 Thousand USD | 365.17% |
| 2013 Q3 | 142.31 Thousand USD | -96.18% |
| 2013 Q2 | 3.72 Million USD | 1217.41% |
| 2013 Q1 | -333.35 Thousand USD | -65.82% |
| 2013 FY | 4.27 Million USD | 414.18% |
| 2012 Q4 | -201.03 Thousand USD | 61.44% |
| 2012 FY | -1.36 Million USD | -146.9% |
| 2012 Q2 | -561.9 Thousand USD | -1505.67% |
| 2012 Q3 | -521.39 Thousand USD | 7.21% |
| 2012 Q1 | -34.99 Thousand USD | 95.4% |
| 2011 FY | 2.9 Million USD | 1574.47% |
| 2011 Q4 | -761.55 Thousand USD | -24.8% |
| 2011 Q1 | -1.04 Million USD | -1292.27% |
| 2011 Q2 | -923.12 Thousand USD | 11.74% |
| 2011 Q3 | -610.2 Thousand USD | 33.9% |
| 2010 FY | -196.71 Thousand USD | -32.6% |
| 2010 Q3 | -48.78 Thousand USD | -29.2% |
| 2010 Q2 | -37.76 Thousand USD | -15.58% |
| 2010 Q1 | -32.67 Thousand USD | -72.64% |
| 2010 Q4 | -75.12 Thousand USD | -53.99% |
| 2009 Q3 | -33.51 Thousand USD | 29.67% |
| 2009 FY | -148.34 Thousand USD | 97.44% |
| 2009 Q4 | -18.92 Thousand USD | 43.53% |
| 2009 Q2 | -47.64 Thousand USD | -27.48% |
| 2009 Q1 | -37.37 Thousand USD | -100.61% |
| 2008 FY | -5.79 Million USD | -398.14% |
| 2008 Q4 | 6.16 Million USD | 198.51% |
| 2008 Q3 | -6.26 Million USD | -4442.17% |
| 2008 Q2 | -137.83 Thousand USD | -17.92% |
| 2008 Q1 | -116.88 Thousand USD | 84.9% |
| 2007 Q4 | -774.26 Thousand USD | -165.98% |
| 2007 Q1 | -2091.71 USD | 85.71% |
| 2007 FY | -1.16 Million USD | -3632.9% |
| 2007 Q2 | -84.34 Thousand USD | -3932.37% |
| 2007 Q3 | -291.09 Thousand USD | -245.12% |
| 2006 Q2 | -6296.00 USD | 45.2% |
| 2006 Q4 | -14.64 Thousand USD | -385.84% |
| 2006 Q3 | -3013.61 USD | 52.13% |
| 2006 FY | -31.15 Thousand USD | -22.82% |
| 2006 Q1 | -11.48 Thousand USD | -216.91% |
| 2005 FY | -25.36 Thousand USD | 0.0% |
| 2005 Q3 | -21.95 Thousand USD | 0.0% |
| 2005 Q4 | -3625.09 USD | 83.49% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 83.52% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 95.637% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 98.767% |
| Nascent Biotech, Inc. | -2.22 Million USD | 90.13% |
| Rebus Holdings, Inc. | -664 Thousand USD | 66.856% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.269% |
| Qrons Inc. | -643.67 Thousand USD | 65.809% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 43.507% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.604% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 47.03% |
| Skye Bioscience, Inc. | -13.67 Million USD | 98.39% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.693% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 104.478% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 15.913% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.71% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 92.279% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 85.672% |
| Mesoblast Limited | -84.14 Million USD | 99.738% |
| Marizyme, Inc. | -34.08 Million USD | 99.354% |
| Genus plc | 6.4 Million USD | 103.439% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 102.259% |
| Pharming Group N.V. | -4.87 Million USD | 95.49% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 88.921% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 76.371% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 97.364% |
| ContraFect Corporation | -56.88 Million USD | 99.613% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 95.168% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 84.302% |
| IMV Inc. | -38.67 Million USD | 99.431% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 92.0% |
| MultiCell Technologies, Inc. | -722.81 USD | -30347.559% |
| ONE Bio Corp. | 13.68 Million USD | 101.609% |
| Accustem Sciences Inc. | -3.74 Million USD | 94.126% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.627% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 54.441% |
| Q BioMed Inc. | -3.44 Million USD | 93.613% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 106.217% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 91.624% |
| Biomind Labs Inc. | -1 Million USD | 78.202% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.6% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 92.414% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 96.69% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 88.196% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -634.769% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 98.613% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 88.612% |
| GB Sciences, Inc. | -1.42 Million USD | 84.507% |
| Alpha Cognition Inc. | -9.7 Million USD | 97.732% |
| HST Global, Inc. | -140.9 Thousand USD | -56.187% |
| CSL Limited | 3.7 Billion USD | 100.006% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 80.436% |
| Halberd Corporation | -75.05 Thousand USD | -193.242% |
| Enzolytics Inc. | -2.14 Million USD | 89.758% |
| Agentix Corp. | -1.37 Million USD | 83.956% |
| Resverlogix Corp. | -12.74 Million USD | 98.274% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 93.054% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.948% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 78.92% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 92.462% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 86.065% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 93.537% |
| AVAX Technologies, Inc. | 6.69 Million USD | 103.288% |
| Zenith Capital Corp. | -8.94 Million USD | 97.539% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.947% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -1163.291% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 91.037% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -28.318% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 89.022% |
| Kadimastem Ltd | -3.04 Million USD | 92.761% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 77.636% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 82.478% |
| BioStem Technologies, Inc. | -7.77 Million USD | 97.171% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -21.265% |
| LadRx Corporation | -3.82 Million USD | 94.244% |
| Cell Source, Inc. | -4.32 Million USD | 94.912% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 67.963% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 67.963% |
| NovAccess Global Inc. | -2.46 Million USD | 91.078% |
| Affymax, Inc. | -15.04 Million USD | 98.537% |
| Itoco Inc. | -919.14 Thousand USD | 76.056% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 94.808% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 80.333% |
| Mobile Lads Corp. | -554.55 Thousand USD | 60.314% |
| CytoDyn Inc. | -18.05 Million USD | 98.781% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -774.366% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 61.029% |
| SYBLEU INC | -149.18 Thousand USD | -47.525% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 87.883% |
| International Stem Cell Corporation | -663 Thousand USD | 66.806% |
| Bioxytran, Inc. | -3.82 Million USD | 94.239% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -318.081% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -981.996% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.393% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 86.398% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 70.091% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 92.926% |
| Neutra Corp. | -229.48 Thousand USD | 4.1% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 98.745% |
| PureTech Health plc | -146.19 Million USD | 99.849% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 98.976% |
| IXICO plc | -1.43 Million USD | 84.685% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 97.681% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.819% |
| CSL Limited | 3.81 Billion USD | 100.006% |
| Cellectis S.A. | -108.85 Million USD | 99.798% |